Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project.

To study the incidence of, the factors associated with, and the effect on survival of anemia in human immunodeficiency virus (HIV)-infected persons, we analyzed data from the longitudinal medical record reviews of 32,867 HIV-infected persons who received medical care from January 1990 through August 1996 in clinics, hospitals, and private medical practices in nine United States cities. We calculated the 1-year incidence of anemia (a hemoglobin level of <10 g/dL or a physician diagnosis of anemia); the adjusted odds ratios showing excess risk of anemia associated with demographic factors, prescribed therapies, and concurrent diseases; the risk of death for patients who developed anemia compared with risk for patients who did not develop anemia; and, of patients who did develop anemia, the risk of death for those who did not recover from anemia compared with the risk for those who did recover. The 1-year incidence of anemia was 36.9% for persons with one or more acquired immunodeficiency syndrome (AIDS)-defining opportunistic illnesses (clinical AIDS), 12.1% for patients with a CD4 count of less than 200 cells/micron or CD4 percentage of <14 but not clinical AIDS (immunologic AIDS), and 3.2% for persons without clinical or immunologic AIDS. Of anemia diagnoses, 22% were identified by physicians as drug related. Incidence of anemia was associated with clinical AIDS, immunologic AIDS, neutropenia, thrombocytopenia, bacterial septicemia, black race, female sex, prescription of zidovudine, fluconazole, and ganciclovir, and lack of prescription of trimethoprim-sulfamethoxazole. The increased risk of death associated with anemia differed by first CD4 count: for patients with a CD4 count of >/=200 cells/microL at the beginning of the survival analysis, the risk of death was 148% (99% confidence interval [CI], 114 to 188) greater for those who developed anemia; for patients whose first CD4 count was <200 cells/microL, the risk of death was 56% (99% CI, 43 to 71) greater for those in whom anemia developed. For persons in whom anemia developed, the risk of death was 170% (99% CI, 132 to 203) greater for persons who did not recover from anemia compared with those who did recover. Anemia is a frequent complication of HIV infection, and its incidence is associated with progression of HIV disease, prescription of certain chemotherapeutics, black race, and female sex. Anemia, particularly anemia that does not resolve, is associated with shorter survival of HIV-infected patients.

[1]  R. Cleveland,et al.  CD4 Expression by erythroid precursor cells in human bone marrow. , 1996, Blood.

[2]  N. Young,et al.  HIV-1 suppression of hematopoiesis in vitro mediated by envelope glycoprotein and TNF-alpha. , 1994, Journal of immunology.

[3]  I. Fraser,et al.  Prophylactic effect of co-trimoxazole for Mycobacterium avium complex infection: a previously unreported benefit. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Pembroke,et al.  Screening for glucose‐6‐phosphate dehydrogenase deficiency prior to dapsone therapy , 1994, Clinical and experimental dermatology.

[5]  K. Gallicano,et al.  Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. , 1994, The Journal of infectious diseases.

[6]  J. Stapleton,et al.  Parvovirus B19 infection in human immunodeficiency virus type 1-infected persons failing or intolerant to zidovudine therapy. , 1993, The Journal of infectious diseases.

[7]  G. Zauli,et al.  tat protein stimulates production of transforming growth factor-beta 1 by marrow macrophages: a potential mechanism for human immunodeficiency virus-1-induced hematopoietic suppression. , 1992, Blood.

[8]  F. Arnalich,et al.  Serum erythropoietin levels in anaemic patients with advanced human immunodeficiency virus infection , 1992, British journal of haematology.

[9]  A. Sampson,et al.  Recombinant Human Erythropoietin in the Treatment of Anemia Associated with Human Immunodeficiency Virus (HIV) Infection and Zidovudine Therapy: Overview of Four Clinical Trials , 1992 .

[10]  P. Mazza,et al.  Evidence for a human immunodeficiency virus type 1-mediated suppression of uninfected hematopoietic (CD34+) cells in AIDS patients. , 1992, The Journal of infectious diseases.

[11]  M. Doukas Human immunodeficiency virus associated anemia. , 1992, The Medical clinics of North America.

[12]  G. Aprili,et al.  Presence and significance of cold agglutinins in patients with HIV infection. , 1992, Haematologica.

[13]  J. Chermann,et al.  The effects of HIV on hematopoiesis , 1992, European journal of haematology.

[14]  C. Reed,et al.  Spectrum of disease in persons with human immunodeficiency virus infection in the United States. , 1992, JAMA.

[15]  Á. Remacha,et al.  Vitamin B‐12 abnormalities in HIV‐infected patients , 1991, European journal of haematology.

[16]  Horsburgh Cr Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. , 1991, The New England journal of medicine.

[17]  B. Böttiger,et al.  Clinical signs and laboratory markers in predicting progression to AIDS in HIV-1 infected patients. , 1991, Scandinavian journal of infectious diseases.

[18]  J. Palmblad,et al.  Trimethoprim‐sulphamethoxazole‐associated blood dyscrasias. Ten years'experience of the Swedish spontaneous reporting system , 1990, Journal of internal medicine.

[19]  J. Groopman Management of the hematologic complications of human immunodeficiency virus infection. , 1990, Reviews of infectious diseases.

[20]  D. Faulds,et al.  Ganciclovir , 1990, Drugs.

[21]  A. Rubinstein,et al.  Hematologic manifestations in pediatric HIV infection: severe anemia as a prognostic factor. , 1990, The American journal of pediatric hematology/oncology.

[22]  T. Quinn,et al.  Serum immunoreactive erythropoietin in HIV-infected patients. , 1989, JAMA.

[23]  N. Mir,et al.  HIV‐disease and bone marrow changes: A study of 60 cases , 1989, European journal of haematology.

[24]  M. Frontiera,et al.  Peripheral blood and bone marrow abnormalities in the acquired immunodeficiency syndrome. , 1987, The Western journal of medicine.

[25]  M A Fischl,et al.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[26]  J. Groopman,et al.  Haematologic manifestations of the human immune deficiency virus (HIV) , 1987, British journal of haematology.

[27]  P. Economopoulos,et al.  Fulminant diarrhoea and acute haemolysis due to G.-6-P.D. deficiency in salmonellosis. , 1973, Lancet.

[28]  J. L. Wilkerson,et al.  The importance of glucose-6-phosphate dehydrogenase screening in a urologic practice. , 1972, The Journal of urology.

[29]  M. Collen,et al.  Prevalence of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency. , 1970, The New England journal of medicine.

[30]  A. Tarlov,et al.  Primaquine sensitivity. Glucose-6-phosphate dehydrogenase deficiency: an inborn error of metabolism of medical and biological significance. , 1962, Archives of internal medicine.